fore, have been inadequate to alter EHV-5 viral loads. Horses with EMPF had a poor outcome in this study. Differences in survival times noted in this study and previous studies may be indicative of varying phenotypes with different rates of progression.
Acknowledgments
The use of valacyclovir in horses in this study was off-label. Sample collection and animal use was approved by the Institutional Animal Care and Use Com-
mittee at the University of California at Davis. Owner consent was obtained for animals used in this study. This Project was funded by the Center for Equine Health, University of California, Davis.
Declaration of Ethics
The Authors have adhered to the Principles of Vet- erinary Medical Ethics of the AVMA.
Conflict of Interest The Authors have no conflicts of interest.